Literature DB >> 6970171

Antigenic modulation of lymphocytic surface immunoglobulin yielding resistance to complement-mediated lysis. II. Relationship to redistribution of the antigen.

J Gordon, G T Stevenson.   

Abstract

Experiments were carried out on guinea-pig L2C leukaemic lymphocytes to investigate the mechanism of antigenic modulation of their surface immunoglobulin (Ig) defined as the conferring by anti-Ig of resistance to lysis by anti-Ig plus complement. The phenomenon reflects, and is probably a consequence of, redistribution of the Ig molecules by bivalent antibody. Fab fragments of the antibody were completely ineffective. Parallel studies by indirect immunofluorescence of the movement of th surface antigen-antibody complexes revealed that modulation for syngeneic complement was apparent when the complexes were minimally aggregated: capping and extensive endocytosis were not necessary. Modulation for xenogeneic (rabbit) complement required more extensive movement but was still appreciable while complexes persisted on the surface. Sodium azide at 10 mM, which inhibits antibody-induced redistribution of surface molecules, diminished modulation. In experiments omitting pre-incubation with antibody alone, the presence of azide during incubations with anti-Ig plus syngeneic complement increased lysis from a low and variable to a consistently high level; there was no effect on the already high level of lysis occurring with the non-modulating anti-Ia plus syngeneic complement. This effect of azide provides further evidence that antigenic modulation can be a major factor determining a cell's survival when it is confronted simultaneously by antibody and complement.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6970171      PMCID: PMC1458209     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  9 in total

1.  Cross-linking of lymphocytic surface immunoglobulin inhibits its production via a cyclic nucleotide mechanism.

Authors:  M Glennie; F K Stevenson; G T Stevenson; M Virji
Journal:  Nature       Date:  1979-09-27       Impact factor: 49.962

2.  Normal distribution, patching and capping of lymphocyte surface immunoglobulin studied by electron microscopy.

Authors:  S de Petris; M C Raff
Journal:  Nat New Biol       Date:  1973-02-28

3.  Mechanism of cytolysis by complement.

Authors:  M M Mayer
Journal:  Proc Natl Acad Sci U S A       Date:  1972-10       Impact factor: 11.205

4.  Modulation of TL (thymus-leukemia) antigens by Fab-fragments of TL antibody.

Authors:  M E Lamm; E A Boyse; L J Old; B Lisowska-Bernstein; E Stockert
Journal:  J Immunol       Date:  1968-07       Impact factor: 5.422

Review 5.  Membrane and cytoplasmic changes in B lymphocytes induced by ligand-surface immunoglobulin interaction.

Authors:  G F Schreiner; E R Unanue
Journal:  Adv Immunol       Date:  1976       Impact factor: 3.543

6.  Different mechanisms for the modulation of TL antigens on murine lymphoid cells.

Authors:  N L Esmon; J R Little
Journal:  J Immunol       Date:  1976-09       Impact factor: 5.422

7.  Surface immunoglobulin of guinea-pig leukaemic lymphocytes.

Authors:  G T Stevenson; R P Eady; D W Hough; R D Jurd; F K Stevenson
Journal:  Immunology       Date:  1975-05       Impact factor: 7.397

8.  Antigenic modulation in vitro. I. Fate of thymus-leukemia (TL) antigen-antibody complexes following modulation of TL antigenicity from the surfaces of mouse leukemia cells and thymocytes.

Authors:  C W Stackpole; J B Jacobson; M P Lardis
Journal:  J Exp Med       Date:  1974-10-01       Impact factor: 14.307

9.  Antibody-induced changes in levels of cyclic adenosine monophosphate in leukaemic lymphocytes.

Authors:  M Virji; G T Stevenson
Journal:  Br J Cancer       Date:  1979-04       Impact factor: 7.640

  9 in total
  12 in total

Review 1.  Bispecific antibody: a tool for diagnosis and treatment of disease.

Authors:  S Songsivilai; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

2.  Development of a bispecific monoclonal antibody against a gallium-67 chelate and the human melanoma-associated antigen p97 for potential use in pretargeted immunoscintigraphy.

Authors:  C Somasundaram; S Matzku; J Schuhmacher; M Zöller
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

3.  Modulation of T-lymphocyte differentiation antigens: potential relevance for multiple sclerosis.

Authors:  J Antel; J J Oger; S Jackevicius; H H Kuo; B G Arnason
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

Review 4.  Treatment of lymphoid tumors with anti-idiotype antibodies.

Authors:  G T Stevenson; F K Stevenson
Journal:  Springer Semin Immunopathol       Date:  1983

5.  Chimeric univalent antibodies for treating lymphoid malignancies.

Authors:  G T Stevenson; V M Cole; J Summerton; H F Watts
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

6.  Immune guided missiles.

Authors:  T J Hamblin
Journal:  Br Med J (Clin Res Ed)       Date:  1982-08-14

Review 7.  Three major uncertainties in the antibody therapy of cancer.

Authors:  George T Stevenson
Journal:  Haematologica       Date:  2014-10       Impact factor: 9.941

8.  Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of antiidiotypic antibody and saporin.

Authors:  M J Glennie; H M McBride; F Stirpe; P E Thorpe; A T Worth; G T Stevenson
Journal:  J Exp Med       Date:  1987-07-01       Impact factor: 14.307

9.  Mechanisms of tumour cell escape encountered in treating lymphocytic leukaemia with anti-idiotypic antibody.

Authors:  J Gordon; A K Abdul-Ahad; T J Hamblin; F K Stevenson; G T Stevenson
Journal:  Br J Cancer       Date:  1984-05       Impact factor: 7.640

10.  Consumption of monoclonal anti-idiotypic antibody by neoplastic B lymphocytes: a guide for immunotherapy.

Authors:  F K Stevenson; M J Glennie; D M Johnston; A L Tutt; G T Stevenson
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.